Fluorescence Guided Surgery Systems Market size was over USD 1.9 billion in 2024 and is estimated to reach USD 4.1 billion by the end of 2037, expanding at a CAGR of 6.8% during the forecast timeline, i.e., 2025-2037. In 2025, the industry size of the fluorescence guided surgery systems is evaluated at USD 2 billion.
The major growth factor of the fluorescence guided surgery systems market is the rising adoption of biomarkers in diagnostics and treatment procedures for several chronic diseases, particularly cancer. In addition, these components function excellently in the process of drug discoveries to introduce innovative therapeutic solutions for such deadly health problems. According to a Research Nester report, the value of the global cancer biomarkers industry is anticipated to reach USD 90.3 billion by the end of 2037. The industry is poised to grow at a 13.7% CAGR, captivating USD 18.6 billion in 2025. The market is further growing with the ongoing improvements and investments in FIS technologies.
Further, the widespread popularity of efficiency and promising results of fluorescence-guided surgeries in a wide range of medical fields has propelled demand in the fluorescence guided surgery systems market. For instance, in October 2024, NLM conducted a study to compare the efficiency and safety of this innovative technique over conventional surgery for colorectal cancer. The results revealed a lower complication rate and intraoperative blood loss during procedures. The higher success rates have also inspired several governing bodies to invest in and implement such technologies across regional healthcare facilities, inflating adoption in this sector. Moreover, increasing focus on minimally invasive surgeries is propelling the demand for innovative treatment methods including this field.
Growth Drivers
Challenges
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
6.8% |
|
Base Year Market Size (2024) |
USD 1.9 billion |
|
Forecast Year Market Size (2037) |
USD 4.1 billion |
|
Regional Scope |
|
Application (Cancer Surgery, Neurosurgery, Ophthalmic Surgery, Cardiac Surgery)
In fluorescence guided surgery systems market, cancer surgery segment is set to cross USD 63.4% billion by 2037. The growing incidences of cancer and fatalities across the world are creating a surge in new and more effective treatment methods. According to a report published by WHO, in February 2024, the estimated number of new cancer and related death cases reached 20 million and 9.7 million respectively in 2022. The total amount of new cases was followed by 2.5 million lung cancer, 2.3 million breast cancer, 1.9 million colorectal cancer, 1.5 million prostate cancer, and 0.9 million stomach cancer. Thus, FGS has become a revolutionary technique in the surgical world for treating such chronic diseases, driving growth in this segment.
Type (Radioactive Tracers, Near-Infrared (NIR) Tracers, Visible Light Tracers)
In terms of type, the radioactive tracers segment is estimated to hold a significant share of the fluorescence guided surgery systems market by the end of 2037. The growth in this segment is attributed to the rising demand for minimally invasive procedures such as Laparoscopy and technological advancements in surgical imaging techniques such as robotic surgery. According to a Research Nester report, the surgical robots market is projected to reach USD 12.5 billion by 2036. The radioactive tracers are capable of transmitting signals even from deeper layers of tissue, making them preferable for precise lesion localization. Such abilities are further driving demand in this segment due to fewer challenges and better patient outcomes during operations.
Our in-depth analysis of the fluorescence guided surgery systems market includes the following segments:
|
Application |
|
|
Type |
|
|
End use |
|
|
Imaging Modalities |
|
|
Target Population |
|
North America Market Analysis
North America fluorescence guided surgery systems market is expected to capture revenue share of over 58.5% by 2037. The growth is driven by the presence of advanced healthcare facilities across the region and the increasing patient population. The governing authorities such as FDA and other institutions are also supporting the progress in this sector through accelerated approvals and funding for FGS products. This is further encouraging domestic leaders to leverage their development and distribution in this field. For instance, in April 2021, OnLume raised a Series A funding of USD 7 million to assist its commercial launch of the FIS system. In addition to the Phase II SBIR grant of USD 2 million from the NIH in 2020, this financial support was dedicated to gathering sufficient resources for future growth.
The U.S. is at the forefront of the regional fluorescence guided surgery systems market due to massive economic growth. As the people of this country become more economically stable, they become eligible to afford such advanced treatments. This creates a good marketplace for this sector and inspires domestic leaders to bring innovation in this field. For instance, in August 2024, SurgicalOne, Inc. partnered with Getinge USA Sales, LLC to help surgeons with greater precision, efficiency, and safety through autofluorescence and fluorescence imaging technology. The team aims to promote advanced imaging solutions by Fluoptics for thyroid/parathyroid and plastic surgery procedures.
Canada is also showing interest in investing in domestic progress in the fluorescence guided surgery systems market by engaging supportive regulations and releasing grants and incentives for R&D. According to a CCS report, published in May 2024, the estimated number of new cancer and death cases was accounted to be 247,100 and 88,100 in the same year. Thus, the country is proactively putting efforts on enhancing healthcare infrastructure to control the growing cancer prevalence. For instance, in January 2023, the Government of Canada announced funding of USD 23 million in childhood cancer research to secure the future generation from this disease. This is influencing global leaders to augment this sector with innovations.
APAC Market Statistics
Asia Pacific is growing significantly in the fluorescence guided surgery systems market with the concerning prevalence cases and extensive R&D efforts to fight against it. The developing countries such as India, Japan, China, and Australia are cultivating resources to develop a well-established healthcare ecosystem across the region. This is creating great opportunities for global leaders to expand their portfolio. For instance, in September 2024, Stryker launched an advanced imaging platform, 1788 to elevate with enhanced imaging capabilities. The new launch aims to solidify the company’s reach throughout the country by elevating surgical visualization across various medical specialties.
India is fostering its own developmental forces to participate in the global fluorescence guided surgery systems market through innovations. According to the 2023 World Bank report, around USD 24.0 million worth of synthetic organic products, used as fluorescent were imported to the country. This is evidence of utilizing such substrates for healthcare innovations. For instance, in August 2024, PIB announced that a team of researchers in IASST developed an affordable, user-friendly, portable smartphone-based fluorescence turn-on sensor system to assist in Parkinson's disease management. Such innovations are setting an example for other domestic leaders to explore deeper in this field.
China is also augmenting regional growth by generating remarkable revenue from the fluorescence guided surgery systems market. Rising demand for advanced imaging and surgical techniques to empower the healthcare infrastructure is fueling the industry. The increasing medical expenditure in the country sets a high hope for established traders in this field. Many domestic medical instrument leaders are also showing interest in investing in R&D to introduce innovative modules.
The dynamics of the global fluorescence guided surgery systems market are shifting towards adoption of next-generation technologies. Research institutions are continuously working to enable AI and machine learning into these devices to reduce operating time and cost. For instance, in December 2020, UCD Centre for Precision Surgery partnered with RCSI’s Department of Chemistry and IBM Research to develop AI-powered decision-making solution to deliver new fluorescence guidance techniques. The team of researchers aimed to penetrate AI methods to enhance specificity in real-time during colorectal cancer surgery while utilizing NIR FGS. Such innovative methods are inspiring key players, including:
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?